Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors.
Dextromethorphan was granted FDA approval before 3 December 1957.
Dextromethorphan is indicated in combination with brompheniramine and pseudoephedrine in the treatment of coughs and upper respiratory symptoms associated with allergies or the common cold. Dextromethorphan is also used in combination with guaifenesin as an over-the-counter product to relieve a cough. Dextromethorphan in combination with quinidine is indicat...
Yale-New Haven Hospital St Raphael, New Haven, Connecticut, United States
Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
UC Irvine Health, Orange, California, United States
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States
Inventiv Health Clinical - Research Pharmacy Unit, Miami, Florida, United States
Jasper Clinic, Kalamazoo, Michigan, United States
Nationwide Children's Hospital, Columbus, Ohio, United States
University of Alabama of Birmingham, Birmingham, Alabama, United States
Center for Family Planning Research, Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
Planned Parenthood of Western Pennsylvania, Pittsburgh, Pennsylvania, United States
University of Washington, Seattle, Washington, United States
National Cheng Kung University Hospital, Tainan, Taiwan
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.